All In Biotech

Drug Trial Radar · NCT06504147

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

A Phase 2, Randomised, Open Label, Multicentre Study of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Patients With Primary Advanced High-grade Serous or High-grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient and Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

Last checked: Nov 19, 2026Latest source record: May 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

114

Planned (sponsor's estimate)

Start

Jun 15, 2024

Primary completion

Feb 29, 2028

Study completion Feb 28, 2031

Sponsor

Lead sponsor
Oncoinvent Solutions ASIndustry
Sponsor type
Industry
First posted
Jul 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are HR proficient and scheduled to undergo NACT and IDS. The study will be conducted in 2 parts; first, a Safety Lead-in Cohort will be recruited followed by the randomised part of the study. For both parts of the study, patients must be scheduled to undergo NACT and IDS and complete resection to no residual tumour (R0) should be deemed to be achievable during diagnostic work-up. Patients in both parts of the study will undergo the same procedures and assessments.

Conditions

  • Peritoneal Carcinomatosis
  • Ovarian Cancer

Interventions

  • RadspherinDrug

    Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survivalTime frame: 24 months

Locations

10 sites in 6 countries. Site status is shown where the registry gives one.

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • UZ Leuven

    Leuven, Belgium · Recruiting

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    Roma, Italy · Recruiting

  • The Norwegian Radiumhospital

    Oslo, Norway · Recruiting

  • Hospital Universitari de Bellvitge

    Barcelona, Spain · Recruiting

  • Clinica Universidad de Navarra

    Madrid, Spain · Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Spain · Recruiting

  • Hospital Universitari i Politècnic La Fe

    Valencia, Spain · Recruiting

  • Imperial College Healthcare NHS Trust

    London, United Kingdom · Recruiting

  • University Hospital Southampton NHS Foundation Trust

    Southampton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.